In contrast to the NF1-deficient glioma lines, and despite successful ATRX knockdown, ATRX loss had no effect on growth in vitro (NF90-8, ST88-14, and JHH-CRC65) or in vivo (NF90-8) (Supplementary Figures S6–S8). This evidence concerns the gene NF1 and central nervous system cancer.